These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11061951)

  • 1. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis.
    Saltel E; Angel JB; Futter NG; Walsh WG; O'Rourke K; Mahoney JE
    J Urol; 2000 Dec; 164(6):1895-7. PubMed ID: 11061951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection.
    Malavaud B; Dinh B; Bonnet E; Izopet J; Payen JL; Marchou B
    Antivir Ther; 2000 Mar; 5(1):3-5. PubMed ID: 10846585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease inhibitor-induced urolithiasis.
    Gentle DL; Stoller ML; Jarrett TW; Ward JF; Geib KS; Wood AF
    Urology; 1997 Oct; 50(4):508-11. PubMed ID: 9338723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of environmental temperature on incidence of indinavir-related nephrolithiasis.
    Martínez E; Leguizamón M; Mallolas J; Miró JM; Gatell JM
    Clin Infect Dis; 1999 Aug; 29(2):422-5. PubMed ID: 10476752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyuria in patients treated with indinavir is associated with renal dysfunction.
    Sarcletti M; Petter A; Romani N; Lhotta K; König P; Maier H; Zangerle R
    Clin Nephrol; 2000 Oct; 54(4):261-70. PubMed ID: 11076101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults.
    Collin F; Chêne G; Retout S; Peytavin G; Salmon D; Bouvet E; Raffi F; Garraffo R; Mentré F; Duval X;
    Ther Drug Monit; 2007 Apr; 29(2):164-70. PubMed ID: 17417069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity.
    Trainor LD; Steinberg JP; Austin GW; Solomon HM
    Arch Pathol Lab Med; 1998 Mar; 122(3):256-9. PubMed ID: 9823864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Crystalluria and nephrolithiasis during therapy with the protease inhibitor indinavir].
    Rickerts V; Kober A; Stille W
    Dtsch Med Wochenschr; 1997 Jun; 122(24):803. PubMed ID: 9229567
    [No Abstract]   [Full Text] [Related]  

  • 9. Urolithiasis associated with the protease inhibitor indinavir.
    Bruce RG; Munch LC; Hoven AD; Jerauld RS; Greenburg R; Porter WH; Rutter PW
    Urology; 1997 Oct; 50(4):513-8. PubMed ID: 9338724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paronychia in association with indinavir treatment.
    Colson AE; Sax PE; Keller MJ; Turk BK; Pettus PT; Platt R; Choo PW
    Clin Infect Dis; 2001 Jan; 32(1):140-3. PubMed ID: 11118393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed.
    Reiter WJ; Schön-Pernerstorfer H; Dorfinger K; Hofbauer J; Marberger M
    J Urol; 1999 Apr; 161(4):1082-4. PubMed ID: 10081842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urinary lithiasis secondary to indinavir in an HIV-positive patient].
    Moyano Calvo JL; Huesa Martínez I; Cruz Navarro N; Leal Arenas J; León Dueñas E; Morales López A; Maestro Durán JL; Ramírez Mendoza A
    Arch Esp Urol; 2001 Dec; 54(10):1117-20. PubMed ID: 11852520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrolithiasis on indinavir.
    Prescrire Int; 1999 Feb; 8(39):22. PubMed ID: 10557573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.
    Boyd MA; Siangphoe U; Ruxrungtham K; Reiss P; Mahanontharit A; Lange JM; Phanuphak P; Cooper DA; Burger DM
    J Antimicrob Chemother; 2006 Jun; 57(6):1161-7. PubMed ID: 16595641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nephrolithiasis in a HIV infected patient treated with indinavir].
    Brzósko S; Hryszko T; Panasiuk B; Prokopowicz D; Myśliwiec M
    Przegl Lek; 2001; 58(6):528-9. PubMed ID: 11816748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.
    Coplan PM; Cook JR; Carides GW; Heyse JF; Wu AW; Hammer SM; Nguyen BY; Meibohm AR; DiNubile MJ;
    Clin Infect Dis; 2004 Aug; 39(3):426-33. PubMed ID: 15307012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of escin on indinavir crystallization time in the urine of patients with HIV-I infection: a multicenter, randomized, open-label, controlled, four-period crossover trial.
    Grases F; García-González R; Redondo E; Costa-Bauzá A; Simonet BM; Sartini RP; Bassa A; Gallegos C; Payeras A; Saro D; Martinez AI; Cifuentes C; Homar F; Murillo JA; Fernández C; Riera M; Conte A
    Clin Ther; 2004 Dec; 26(12):2045-55. PubMed ID: 15823768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
    Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy.
    Palacios R; Merchante N; Macias J; González M; Castillo J; Ruiz J; Márquez M; Gómez-Mateos J; Pineda JA; Santos J
    Antivir Ther; 2006; 11(4):529-35. PubMed ID: 16856627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.